Patents by Inventor Andrew HAMMET

Andrew HAMMET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20230086472
    Abstract: A serum albumin variant, or functional fragment thereof, comprising, one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Application
    Filed: August 30, 2022
    Publication date: March 23, 2023
    Applicant: CSL Limited
    Inventors: Sabine RAUTH, Andrew HAMMET, Kirsten Edwards, Con PANOUSIS
  • Human serum albumin variants and uses thereof
    Patent number: 11466073
    Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 11, 2022
    Assignee: CSL Limited
    Inventors: Sabine Rauth, Andrew Hammet, Kirsten Edwards, Con Panousis
  • METHOD OF INHIBITING OR ACTIVATING GAMMA DELTA T CELLS
    Publication number: 20220273713
    Abstract: The present disclosure relates to methods for inhibiting activation of ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.
    Type: Application
    Filed: June 26, 2020
    Publication date: September 1, 2022
    Applicants: The University of Melbourne, Olivia Newton-John Cancer Research Institute, CSL INNOVATION PTY LTD
    Inventors: Andreas BEHREN, Jonathan CEBON, Marc Rigau CORTAL, Thomas Samuel FULFORD, Dale Ian GODFREY, Andrew HAMMET, Simone OSTROUSKA, Con PANOUSIS, Adam Peter ULDRICH
  • METHOD OF TREATING CANCER
    Publication number: 20210292411
    Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.
    Type: Application
    Filed: November 4, 2020
    Publication date: September 23, 2021
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20200325209
    Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Application
    Filed: October 18, 2018
    Publication date: October 15, 2020
    Applicant: CSL Limited
    Inventors: Sabine RAUTH, Andrew HAMMET, Kirsten EDWARDS, Con PANOUSIS
  • METHOD OF TREATING CANCER
    Publication number: 20190023783
    Abstract: The present disclosure provides computer-implemented methods of organising the marketing of a compound that neutralises BTN2A1.
    Type: Application
    Filed: July 31, 2018
    Publication date: January 24, 2019
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • METHOD OF TREATING CANCER
    Publication number: 20160376364
    Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.
    Type: Application
    Filed: November 28, 2014
    Publication date: December 29, 2016
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS